Karyopharm Therapeutics Inc. (NASDAQ:KPTI) Short Interest Update

Karyopharm Therapeutics Inc. (NASDAQ:KPTI) saw a large increase in short interest in February. As of February 13th, there was short interest totaling 2,466,525 shares, an increase of 82.5% from the January 29th total of 1,351,651 shares. Based on an average daily volume of 853,907 shares, the short-interest ratio is currently 2.9 days. Currently, 13.7% of the shares of the stock are sold short. Currently, 13.7% of the shares of the stock are sold short. Based on an average daily volume of 853,907 shares, the short-interest ratio is currently 2.9 days.

Institutional Investors Weigh In On Karyopharm Therapeutics

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in KPTI. XTX Topco Ltd acquired a new stake in Karyopharm Therapeutics in the 2nd quarter worth approximately $56,000. Silverback Asset Management LLC raised its position in shares of Karyopharm Therapeutics by 40.0% in the second quarter. Silverback Asset Management LLC now owns 70,000 shares of the company’s stock valued at $302,000 after purchasing an additional 20,000 shares during the period. Baird Financial Group Inc. acquired a new stake in shares of Karyopharm Therapeutics in the second quarter worth $45,000. Bank of America Corp DE boosted its holdings in shares of Karyopharm Therapeutics by 26.8% during the 2nd quarter. Bank of America Corp DE now owns 168,534 shares of the company’s stock worth $726,000 after buying an additional 35,626 shares during the period. Finally, Bridgeway Capital Management LLC bought a new stake in shares of Karyopharm Therapeutics during the 2nd quarter worth $163,000. Hedge funds and other institutional investors own 66.44% of the company’s stock.

Analyst Ratings Changes

A number of research firms recently commented on KPTI. Cantor Fitzgerald began coverage on shares of Karyopharm Therapeutics in a report on Thursday, February 5th. They issued an “overweight” rating on the stock. HC Wainwright reaffirmed a “buy” rating and issued a $15.00 price target on shares of Karyopharm Therapeutics in a report on Wednesday, February 18th. Weiss Ratings reissued a “sell (d-)” rating on shares of Karyopharm Therapeutics in a research note on Monday, December 29th. Piper Sandler restated an “overweight” rating and issued a $12.00 target price on shares of Karyopharm Therapeutics in a report on Wednesday, December 17th. Finally, Royal Bank Of Canada reduced their target price on Karyopharm Therapeutics from $30.00 to $19.00 and set an “outperform” rating for the company in a report on Tuesday, November 4th. Six analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, Karyopharm Therapeutics presently has an average rating of “Moderate Buy” and an average target price of $14.83.

Karyopharm Therapeutics Stock Performance

NASDAQ:KPTI traded up $0.06 during trading hours on Friday, hitting $9.41. 529,971 shares of the company’s stock traded hands, compared to its average volume of 685,656. The stock’s fifty day moving average price is $7.59 and its two-hundred day moving average price is $6.62. The firm has a market cap of $172.58 million, a P/E ratio of -0.57 and a beta of 0.21. Karyopharm Therapeutics has a twelve month low of $3.51 and a twelve month high of $10.99.

Karyopharm Therapeutics (NASDAQ:KPTI) last released its earnings results on Friday, February 13th. The company reported ($2.23) earnings per share for the quarter, beating the consensus estimate of ($2.26) by $0.03. The business had revenue of $34.08 million for the quarter, compared to analysts’ expectations of $33.16 million. On average, equities research analysts predict that Karyopharm Therapeutics will post -0.71 earnings per share for the current year.

Karyopharm Therapeutics Company Profile

Karyopharm Therapeutics (NASDAQ: KPTI) is a clinical-stage biopharmaceutical company focused on discovering and developing novel first-in-class drugs that target the nuclear export protein XPO1. The company’s lead product, selinexor (marketed as XPOVIO), is an oral selective inhibitor of nuclear export (SINE) compound approved for treatment of multiple myeloma and diffuse large B-cell lymphoma. In addition to selinexor, Karyopharm’s pipeline includes second-generation SINE compounds and combination studies in solid tumors and hematologic malignancies.

Founded in 2008 and headquartered in Newton, Massachusetts, Karyopharm has built a research platform around modulation of nuclear export pathways.